Top Trends Driving Innovation and Change in the Primary Ciliary Dyskinesia (PCD) Market: Advancements In mRNA-Based Therapies For Primary Ciliary Dyskinesia Treatment
We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Has the Primary Ciliary Dyskinesia (PCD) Market Growth Performance Trended Historically, And What Lies Ahead?
The market size of primary ciliary dyskinesia has seen substantial growth in recent times. The market value is projected to increase from $0.46 billion in 2024 to $0.50 billion in 2025, showing a compound annual growth rate (CAGR) of 7.1%. The upward trend in the past can be linked to increased cases of clinical confusion with other respiratory diseases, a greater dependence on symptomatic treatments, increased adoption of general respiratory therapies, a rise in diagnoses based on exclusion tactics and a growing emphasis on cystic fibrosis overlooking primary ciliary dyskinesia.
The market size for primary ciliary dyskinesia is projected to witness a notable surge in the years to come. By 2029, it is predicted to reach a valuation of $0.65 billion, expanding at a compound annual growth rate (CAGR) of 6.8%. The significant growth during this forecast timeline can be linked to factors such as increased consciousness about unusual respiratory illnesses, enhanced accessibility to genetic testing facilities, a rise in instances of persistent respiratory infections, better reimbursement schemes, and the establishment of more specialty diagnostic facilities. The forecast period also sees key trends such as the evolution of genetic sequencing technology, the creation of non-intrusive diagnostic tools, a rise in research and development collaborations, breakthroughs in airway clearance devices, and the incorporation of artificial intelligence in diagnostic imaging techniques.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24386&type=smp
What External and Internal Drivers Are Contributing to the Growth of the Primary Ciliary Dyskinesia (PCD) Market?
The primary ciliary dyskinesia market stands to benefit from the growing interest in gene therapy. Gene therapy refers to the process of amending or replacing defective genes in a patient’s cells with the aim of curing or preventing ailments. Genetic research advancements are bolstering the demand for gene therapy by paving the way for more precision-based treatments that tackle genetic disorders at a molecular level, thereby leading to improved patient outcomes. Scientists are in the process of creating a gene therapy specifically for Primary Ciliary Dyskinesia (PCD), which aims to rectify the genetic anomalies responsible for the improper functioning of cilia in the respiratory system. This therapy is expected to reintroduce healthy genes to reestablish normal cilia activity, boost mucus clearance, and diminish respiratory infections. The American Society of Gene & Cell Therapy (ASGCT), a professional membership organization based in the U.S, reported that in July 2023, the first quarter saw 247 Phase II clinical trials for gene therapy programs, marking a 5% growth to reach a total of 260 ongoing Phase II gene therapy trials by the end of the second quarter. Therefore, it can be said that the burgeoning demand for gene therapy is spurring the expansion of the primary ciliary dyskinesia market.
What Segment Types Define the Primary Ciliary Dyskinesia (PCD) Market Structure?
The primary ciliary dyskinesia (PCD) market covered in this report is segmented –
1) By Treatment: Antibiotics, Airway Clearance Therapies, Surgical Interventions, Other Treatments
2) By Method: Genetic Testing, Imaging Techniques, Clinical Evaluation, Lung Function Tests
4) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Retail Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Antibiotics: Macrolides, Penicillins, Cephalosporins, Fluoroquinolones, Aminoglycosides
2) By Airway Clearance Therapies: Chest Physiotherapy, High-Frequency Chest Wall Oscillation (HFCWO), Positive Expiratory Pressure (PEP) Therapy, Intrapulmonary Percussive Ventilation (IPV), Oscillatory Positive Expiratory Pressure (OPEP)
3) By Surgical Interventions: Sinus Surgery, Tympanostomy Tube Placement, Lung Transplantation
4) By Other Treatments: Mucolytics, Immunomodulatory Therapies, Gene Therapy, Stem Cell Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24386&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Primary Ciliary Dyskinesia (PCD) Market?
North America was the largest region in the primary ciliary dyskinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary ciliary dyskinesia (PCD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Primary Ciliary Dyskinesia (PCD) Market?
Leading corporations in the primary ciliary dyskinesia market are concentrating on devising innovative solutions like investigational mRNA-based therapeutics to enhance symptom control and improve patient’s wellbeing. This emerging treatment, using messenger RNA (mRNA), instructs cells to generate proteins that can potentially treat or eradicate diseases. This advanced approach addresses illnesses at the molecular level, facilitating the advent of personalized medicine. For instance, ReCode Therapeutics, Inc., a biotech company based in the U.S., introduced RCT1100, a novel inhaled mRNA therapy, in June 2024. This methodology received the FDA’s approval for orphan drug designation to address primary ciliary dyskinesia. RCT1100 is designed to reestablish ciliary function by conveying DNAI1 mRNA directly to the cells of the airway, thereby meeting a significant unmet requirement for the estimated 45,000 U.S. individuals suffering from this condition. Currently, there are no curative or disease-altering treatments available for PCD.
View the full report here:
What Is the Definition of the Primary Ciliary Dyskinesia (PCD) Market?
Primary ciliary dyskinesia (PCD) is a rare inherited disorder that impairs cilia’s normal function and structure, a microscopic, hair-like structure found in the airways, ears, and reproductive tract. The primary purpose of understanding and diagnosing PCD is to manage symptoms early and improve quality of life through targeted therapies.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/customise?id=24386&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
